Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy

American Heart Journal

Volumn 149, Issue 1, 2005, Pages 138-144

  Denardo, Scott J ^a   Davis, Keith E ^a   Tcheng, James E ^b  

^a FirstHealth Carolinas/Moore Reg H   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY STENT; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; Q WAVE; THROMBOCYTOPENIA;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE;

EID: 12344281820     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.06.002     Document Type: Article

References (42)

1. Harker L.A. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol. 60:1987;20B-28B
2. Willerson J.T., Golino P., Eidt J., et al. Specific platelet mediators and unstable coronary artery lesions experimental evidence and potential clinical implications. Circulation. 80:1989;198-205
3. Tracy PB. Role of platelets and leukocytes in coagulation. In: Coleman RW,Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis: basicprinciples and clinical practice. 4th ed. Philadelphia: LippincottWilliams and Wilkins; 2001. p.575-96
4. Harrington R.A. Platelet inhibition in cardiovascular disease management aspirin and beyond. J Thromb Thrombolysis. 5:(Suppl1):1998;37-41
5. Gruntzig A.R., Myler R.K., Hanna E.S., et al. Transluminal angioplasty of coronary artery stenosis. Circulation. 56:(supplII):1977;84
6. Harrington R.A., Kleinman N.S., Kottke-Marchant K., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 76:1995;1222-1227
7. Coller B.S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the glycoprotein IIb/IIIa complex. J Clin Invest. 76:1985;101-108
8. Butenas S., Cawthern K.M., van't Veer C., et al. Antiplatelet agents in tissue factor-induced blood coagulation. Blood. 97:2001;2314-2322
9. Reverter J.C., Beguin S., Kessels H., et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest. 98:1996;863-874
10. Calverley D.C., Roth G.J. Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. Hematol Oncol Clin North Am. 12:1998;1231-1249
11. Theroux P., Waters D., Lam J., et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 327:1992;141-145
12. Smith A.J., Holt R.E., Fitzpatrick J.B., et al. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J. 131:1996;434-439
13. Matthai W.H., Kurnik P.B., Groh W.C., et al. Antithrombin activity during the period of coronary revascularization Relation to heparin use, thrombotic complications and restenosis. J Am Coll Cardiol. 33:1999;1248-1256
14. Knight C.J., Panesar M., Wilson D.J., et al. Increased platelet responsiveness following coronary stenting heparin as a possible etiological factor in stent thrombosis. Eur Heart J. 19:1998;1239-1248
15. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 97:1998;251-256
16. Ashby D.T., Dangas G., Aymong E.A., et al. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. Am J Cardiol. 92:2003;319-322
17. Brieger D.B., Mak K.H., Kottke-Marchant K., et al. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 31:1998;1449-1459
18. Ferguson J.J., Dougherty K.G., Gaos C.M., et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 23:1994;1061-1065
19. McGarry T.F., Gottlieb R.S., Morganroth J., et al. The relationship of anticoagulation level, and the complications after successful coronary angioplasty. Am Heart J. 123:1992;1445-1451
20. Narins C.R., Hillegass W.B., Nelson C.L., et al. Relationship between activated clotting time during angioplasty and abrupt closure. Circulation. 93:1996;667-671
21. Chew D.P., Bhatt D.L., Lincoff A.M., et al. Defining the optimal activated clotting time during percutaneous coronary intervention aggregate results from 6 randomized, controlled trials. Circulation. 103:2001;961-966
22. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II. Lancet. 349:1997;1422-1428
23. O'Shea J.C., Hafley G.E., Greenberg S., et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention the ESPRIT trial: a randomized controlled trial. JAMA. 285:2001;2468-2473
24. Gilchrist I.C., O'Shea J.C., Kosoglou T., et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 104:2001;406-411
25. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961
26. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696
27. CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before, during and after coronary intervention in refractory unstable angina the CAPTURE study. Lancet. 349:1997;1429-1435
28. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 352:1998;87-92
29. Stone G.W., Moliterno D.J., Bertrand M., et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting the TARGET trial. Circulation. 105:2002;2347-2354
30. Mehta S.R., Yusuf S., Peters R.J.G., et al. Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary intervention the PCI-CURE study. Lancet. 358:2001;527-533
31. Boccara A., Benamer J.-M., Juliard P., et al. A randomized trial of a fixed high dose vs. a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J. 18:1997;631-635
32. Koch K.T., Piek J.J., de Winter R.J., et al. Safety of low dose heparin in elective angioplasty. Heart. 77:1997;517-522
33. Denardo S.J., Davis K.E., Reid P.R., et al. Efficacy and safety of minimal dose (≤ 1000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. Am J Cardiol. 91:2003;1-5
34. Belmont Report: ethical principles and guidelines for the protection of human subjects of research. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Fed Regist. 44:1979;23192-23197
35. Preventionof venous thromboembolism: international consensus statement(guidelines according to clinical evidence). Int Angiol 16;1997:3-38
36. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11
37. Glantz SA. Primer of biostatistics. New York: McGraw-Hill; 1992. Chapter7
38. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA. 289:2003;853-863
39. Blankenship J.C., Sigmon K.N., Pieper K.S., et al. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II trial. Am J Cardiol. 88:2001;969-973
40. Islam M.A., Blankenship J.C., Balog C., et al. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Am J Cardiol. 90:2002;916-921
41. Tolleson T.R., O'Shea J.C., Bittl J.A., et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention observations from the ESPRIT trial. J Am Coll Cardiol. 41:2003;386-393
42. Ray J.G. Evidence in upheaval. Incorporating observational data into clinical practice. Arch Intern Med. 162:2002;249-254